A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.
Purpose: This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient refusal or withdrawal of patient consent, or unacceptable toxicity.
Purpose: This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment has been closed for the following cohorts: non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and metastatic colorectal cancer (mCRC).
Purpose: This is a single-arm phase II trial to assess the biological activity (in a sub-cohort using a Simon two-stage Phase II design) and toxicity of Artichoke Whole Phytocomplex Concentrate (WPC). The objective of the study is to explore the potential for a non-toxic phytocomplex extract from the artichoke plant as a chemoprevention agent.
Please note: the estimated primary completion date for this study of August, 2015 has passed. However, it is not listed as closed by ClinicalTrials.gov. Inquire with the study contacts (view full clinical tiral post) to determine if they are still accepting participants or for more information about the treatment protocol.
Purpose: SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.
Purpose: The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells (DCs) – engineered to express the WT1 protein – in patients with limited spread metastatic solid tumors, i.e. breast cancers, glioblastoma grade IV, sarcomas, malignant mesothelioma and colorectal tumors. Based on the results of our previously performed phase I study with autologous WT1 mRNA-transfected DC, the investigators hypothesize that the vaccination with DC will be well-tolerated and will result in an increase in WT1-specific CD8+ T cell responses.
Please note: the estimated primary completion date for this study of February, 2014 has passed. However, it is not listed as closed by ClinicalTrials.gov. Inquire with the study contacts (view full clinical tiral post) to determine if they are still accepting participants or for more information about the treatment protocol.
To Study the Effect of Polymorphism in Fas Ligand gene Promoter Region (rs 763110) on Gemcitabine/Platinum regimens used in treatment of malignant pleural mesothelioma (MPM)
Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung and thymic cancers to understand the disease better. This may lead to new ways to diagnose and treat it.
To collect tissue samples for use in the study of lung cancers
Adults over age 18 with non-small cell lung cancer, small cell lung cancer, extra pulmonary small cell cancer, pulmonary neuroendocrine tumors, and thymic epithelial tumors.
- Participants will be screened with a medical history, physical exam, and blood tests. They will be asked about how they perform their daily tasks.
- Participants may be asked to give urine and blood samples. They may give a saliva sample if they cannot give blood. They will also give a sample of their tumor from a biopsy they had. They may also be given the option to undergo a biopsy.
- Participants may have MRI, CT, and/or PET scans of the body. They will lie in a machine that takes pictures of the body.
- After visits to the Clinical Center end, researchers will contact participants by phone every year to check on their health.
Purpose: The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Purpose: BAY94-9343 is an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells. This study will attempt to answer the following questions:
- What are the side effects of BAY94-9343 when given at different dose levels and schedules?
- What dose level and schedule of BAY94-9343 should be tested in future clinical research studies?
- How much BAY94-9343 is in the blood at specific times after administration?
- Does the treatment with BAY94-9343 show any effect on the tumor growth?
- Are there specific biomarkers that might be able to explain why some patients respond to treatment and others do not?
Please note: the estimated primary completion date for this study of March, 2015 has passed. However, it is not listed as closed by ClinicalTrials.gov. Inquire with the study contacts (view full clinical tiral post) to determine if they are still accepting participants or for more information about the treatment protocol.
Purpose: The purpose of this signal seeking study is to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.